IMMUNIC, INC.
IMUXDrugs in Pipeline
3
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
TomorrowMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
IMUX Earnings Report
EPS Est: $-1.24 | FQ end 2026-06
How IMUX's past catalysts played out
IMU-838 tablets
Multiple Sclerosis, Relapsing-Remitting
IMU-838
Multiple Sclerosis
IMU-838 (30 mg/day)
Relapsing-Remitting Multiple Sclerosis (RRMS)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
IMU-838 tablets | Phase 3 | Multiple Sclerosis, Relapsing-Remitting | - | - |
IMU-838 | Phase 3 | Multiple Sclerosis | - | - |
IMU-838 (30 mg/day) | Phase 2 | Relapsing-Remitting Multiple Sclerosis (RRMS) | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in IMMUNIC, INC.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in IMMUNIC, INC.'s (IMUX) pipeline across Phase 3, Phase 2. Its lead program is IMU-838 tablets (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is IMMUNIC, INC.'s next FDA catalyst?→
IMMUNIC, INC.'s (IMUX) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track IMUX biotech catalysts?→
Add IMUX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow IMMUNIC, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.